Recent advances in targeted drug delivery approaches using dendritic polymers.

Since they were first synthesized over 30 years ago, dendrimers have seen rapid translation into various biomedical applications. A number of reports have not only demonstrated their clinical utility, but also revealed novel design approaches and strategies based on the elucidation of underlying mechanisms governing their biological interactions. This review focuses on presenting the latest advances in dendrimer design, discussing the current mechanistic understandings, and highlighting recent developments and targeted approaches using dendrimers in drug/gene delivery.

[1]  Marta Sowinska,et al.  Advances in the chemistry of dendrimers , 2014 .

[2]  F. Szoka,et al.  Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. , 2002, Bioconjugate chemistry.

[3]  E. Simanek,et al.  Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers. , 2012, Molecular pharmaceutics.

[4]  F. Szoka,et al.  Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. , 2010, Bioconjugate chemistry.

[5]  W. Driessen,et al.  Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. , 2014, Journal of the American Chemical Society.

[6]  E. Laurini,et al.  Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencing. , 2013, Molecular pharmaceutics.

[7]  Wei Li,et al.  Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. , 2011, Cancer research.

[8]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[9]  Seungpyo Hong,et al.  Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. , 2006, Bioconjugate chemistry.

[10]  P. Hildgen,et al.  Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. , 2008, Molecular pharmaceutics.

[11]  E. Murugan,et al.  Drug delivery investigations of quaternised poly(propylene imine) dendrimer using nimesulide as a model drug. , 2014, Colloids and surfaces. B, Biointerfaces.

[12]  J. Fréchet,et al.  Fast and convenient divergent synthesis of aliphatic ester dendrimers by anhydride coupling. , 2001, Journal of the American Chemical Society.

[13]  Shirley Dex,et al.  JR 旅客販売総合システム（マルス）における運用及び管理について , 1991 .

[14]  H. Frey,et al.  Linear–dendritic block copolymers: The state of the art and exciting perspectives , 2011 .

[15]  Jean M. J. Fréchet,et al.  Hyperbranched macromolecules via a novel double-stage convergent growth approach , 1991 .

[16]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[17]  Ben J. Boyd,et al.  Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. , 2012, Molecular pharmaceutics.

[18]  Fumiyoshi Yamashita,et al.  Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[19]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. Brechbiel,et al.  3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.

[21]  J. Fréchet,et al.  Discovery of dendrimers and dendritic polymers: A brief historical perspective* , 2002 .

[22]  F. Szoka,et al.  PEGylated dendrimers with core functionality for biological applications. , 2008, Bioconjugate chemistry.

[23]  D. Owen,et al.  Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Manouchehr Mirshahi,et al.  Efficacy of dendrimer‐mediated angiostatin and TIMP‐2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies , 2003, International journal of cancer.

[25]  Prateek Singh,et al.  Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. , 2008, Bioconjugate chemistry.

[26]  B. Orr,et al.  Deformability of poly(amidoamine) dendrimers , 2004, The European physical journal. E, Soft matter.

[27]  L. Kaminskas,et al.  Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. , 2011, Nanomedicine.

[28]  F. Szoka,et al.  Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates. , 2009, Molecular pharmaceutics.

[29]  B. Ross,et al.  Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors , 2009, Journal of Neuro-Oncology.

[30]  Li Wang,et al.  A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. , 2009, Biomaterials.

[31]  Ryan M. Pearson,et al.  Kinetically Controlled Cellular Interactions of Polymer-polymer and Polymer-liposome Nanohybrid Systems , 2022 .

[32]  W. Marsden.  I and J , 2012 .

[33]  D. Tomalia,et al.  CommentaryDendrimers in biomedical applications—reflections on the field☆☆☆ , 2012 .

[34]  Seungpyo Hong,et al.  The Binding Avidity of a Nanoparticle-based Multivalent Targeted Drug Delivery Platform , 2022 .

[35]  Seungpyo Hong,et al.  The role of ganglioside GM1 in cellular internalization mechanisms of poly(amidoamine) dendrimers. , 2009, Bioconjugate chemistry.

[36]  Mingming Wang,et al.  The effect of fluorination on the transfection efficacy of surface-engineered dendrimers. , 2014, Biomaterials.

[37]  Seungpyo Hong,et al.  Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[38]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[39]  Ruth Duncan,et al.  Anionic PAMAM Dendrimers Rapidly Cross Adult Rat Intestine In Vitro: A Potential Oral Delivery System? , 2000, Pharmaceutical Research.

[40]  N. Chiaramoni,et al.  Optimization and In Vivo Toxicity Evaluation of G4.5 Pamam Dendrimer-Risperidone Complexes , 2014, PloS one.

[41]  A. Caminade,et al.  A Phosphorus-Based Dendrimer Targets Inflammation and Osteoclastogenesis in Experimental Arthritis , 2011, Science Translational Medicine.

[42]  M. Adeli,et al.  Carbon nanotubes in cancer therapy: a more precise look at the role of carbon nanotube-polymer interactions. , 2013, Chemical Society reviews.

[43]  E. W. Meijer,et al.  About Dendrimers: Structure, Physical Properties, and Applications. , 1999, Chemical reviews.

[44]  T. Xu,et al.  NMR insights into dendrimer-based host-guest systems. , 2012, Chemical reviews.

[45]  R. Stephenson.  A and V , 1962, The British journal of ophthalmology.

[46]  Wojciech G. Lesniak,et al.  Dendrimer Brain Uptake and Targeted Therapy for Brain Injury in a Large Animal Model of Hypothermic Circulatory Arrest , 2014, ACS nano.

[47]  N. K. Jain,et al.  Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. , 2014, Biomaterials.

[48]  S. Kannan,et al.  The effect of surface functionality on cellular trafficking of dendrimers. , 2008, Biomaterials.

[49]  L. Kaminskas,et al.  Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. , 2012, Molecular pharmaceutics.

[50]  L. Kaminskas,et al.  Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. , 2007, Molecular pharmaceutics.

[51]  K. Winnicka,et al.  The Effect of Generation 2 and 3 Poly(amidoamine) Dendrimers on Viability of Human Breast Cancer Cells , 2009 .

[52]  N. McKeown,et al.  The influence of surface modification on the cytotoxicity of PAMAM dendrimers. , 2003, International journal of pharmaceutics.

[53]  Mingming Wang,et al.  A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios , 2014, Nature Communications.

[54]  A. Richardson,et al.  Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor. , 2014, ACS medicinal chemistry letters.

[55]  T. Niidome,et al.  Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. , 2012, Molecular pharmaceutics.

[56]  Hisataka Kobayashi,et al.  Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. , 2010, International journal of pharmaceutics.

[57]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.

[58]  Charles L. Wilkins,et al.  Double Exponential Dendrimer Growth , 1995 .

[59]  Chelsea E T Stowell,et al.  Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. , 2012, Biomacromolecules.

[60]  L. Kaminskas,et al.  PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[61]  A. Caminade,et al.  Dendrimers for drug delivery. , 2014, Journal of materials chemistry. B.

[62]  Y. Pei,et al.  PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: In Vitro Evaluation and In Vivo Tumor Accumulation , 2010, Pharmaceutical Research.

[63]  Seungpyo Hong,et al.  Differential Detection of Tumor Cells Using a Combination of Cell Rolling, Multivalent Binding, and Multiple Antibodies , 2014, Analytical chemistry.

[64]  Ryan M. Pearson,et al.  Dendritic nanoparticles: the next generation of nanocarriers? , 2012, Therapeutic delivery.

[65]  Joseph M. Wallace,et al.  RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. , 2009, Bioconjugate chemistry.

[66]  Seungpyo Hong,et al.  Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. , 2004, Bioconjugate chemistry.

[68]  P Posocco,et al.  Tell me something I do not know. Multiscale molecular modeling of dendrimer/ dendron organization and self-assembly in gene therapy. , 2012, Current medicinal chemistry.

[69]  Ryan M. Pearson,et al.  Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery , 2013 .

[70]  S. Kawakami,et al.  Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations , 2011, Pharmaceutical Research.

[71]  Y. Liu,et al.  In vitro evaluation of dendrimer-polymer hybrid nanoparticles on their controlled cellular targeting kinetics. , 2013, Molecular pharmaceutics.

[72]  Ryan M. Pearson,et al.  Dendron‐Based Micelles for Topical Delivery of Endoxifen: A Potential Chemo‐Preventive Medicine for Breast Cancer , 2014 .

[73]  Yu Wang,et al.  Fluorinated poly(propylenimine) dendrimers as gene vectors. , 2014, Biomaterials.

[74]  J. Ong,et al.  Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. , 2014, Molecular pharmaceutics.

[75]  Jason E Gestwicki,et al.  Synthetic multivalent ligands as probes of signal transduction. , 2006, Angewandte Chemie.

[76]  Vaibhav Jain,et al.  Pharmacoinformatic approaches to understand complexation of dendrimeric nanoparticles with drugs. , 2014, Nanoscale.

[77]  C. Liu,et al.  Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo. , 2014, Bioconjugate chemistry.

[78]  T. Minko,et al.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[79]  Fabio Beltram,et al.  Dendrimer internalization and intracellular trafficking in living cells. , 2010, Molecular pharmaceutics.

[80]  Sabrina Pricl,et al.  Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. , 2012, Molecular pharmaceutics.

[81]  A. Tkachenko,et al.  Kinetic limitations of cooperativity-based drug delivery systems. , 2007, Physical review letters.

[82]  J. Fréchet,et al.  A Rapid, Orthogonal Synthesis of Poly(benzyl ester) Dendrimers via an “Activated” Monomer Approach , 1999 .

[83]  Jiahai Zhang,et al.  Host-guest chemistry of dendrimer-drug complexes: 7. Formation of stable inclusions between acetylated dendrimers and drugs bearing multiple charges. , 2012, The journal of physical chemistry. B.

[84]  C. Hawker,et al.  Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules , 1990 .

[85]  M. Adeli,et al.  Impact of dendritic polymers on nanomaterials , 2015 .

[86]  J. B. Christensen,et al.  Dendrimers: Design, Synthesis and Chemical Properties , 2006 .

[87]  D. Owen,et al.  Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[88]  C. Liu,et al.  An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo. , 2012, Angewandte Chemie.

[89]  E. Gillies,et al.  Surface functionalization of nanomaterials with dendritic groups: toward enhanced binding to biological targets. , 2009, Journal of the American Chemical Society.

[90]  Ziwei Zhang,et al.  Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells , 2014, Journal of drug targeting.

[91]  Arwin J. Brouwer,et al.  Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. , 2007, Organic & biomolecular chemistry.

[92]  Ryan M. Pearson,et al.  Temporal control over cellular targeting through hybridization of folate-targeted dendrimers and PEG-PLA nanoparticles. , 2012, Biomacromolecules.

[93]  L. Vannucci,et al.  Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. , 2003, International journal of oncology.

[94]  R. Kabiri,et al.  Preparation of hybrid nanomaterials by supramolecular interactions between dendritic polymers and carbon nanotubes , 2013 .

[95]  L. Kiessling,et al.  Synthetic multivalent ligands in the exploration of cell-surface interactions. , 2000, Current opinion in chemical biology.

[96]  M. Zloh,et al.  Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. , 2013, ACS nano.

[97]  D. Tomalia,et al.  Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.

[98]  Ryan M. Pearson,et al.  Understanding nano-bio interactions to improve nanocarriers for drug delivery , 2014 .

[99]  Yu-qiang Ma,et al.  Theoretical and computational studies of dendrimers as delivery vectors. , 2013, Chemical Society reviews.

[100]  Umesh Gupta,et al.  Ligand based dendritic systems for tumor targeting. , 2008, International journal of pharmaceutics.

[101]  Hamidreza Ghandehari,et al.  Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. , 2008, Molecular pharmaceutics.

[102]  Guangji Wang,et al.  Synthesis and characterization of multi-functional linear-dendritic block copolymer for intracellular delivery of antitumor drugs. , 2013, International journal of pharmaceutics.

[103]  Catherine Santaella,et al.  Highly fluorinated amphiphiles as drug and gene carrier and delivery systems , 2001 .

[104]  Seungpyo Hong,et al.  Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells. , 2011, Angewandte Chemie.

[105]  Ling Peng,et al.  PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. , 2006, Chemical communications.

[106]  Xiangyang Shi,et al.  Impact of dendrimer surface functional groups on the release of doxorubicin from dendrimer carriers. , 2014, The journal of physical chemistry. B.

[107]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[108]  Thommey P. Thomas,et al.  Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.

[109]  Seungpyo Hong,et al.  Nanoscale polymeric penetration enhancers in topical drug delivery , 2013 .

[110]  Steven C. Zimmerman,et al.  Rapid synthesis of dendrimers by an orthogonal coupling strategy , 1996 .

[111]  A. Shakhbazau,et al.  How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[112]  L. Kaminskas,et al.  Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. , 2009, Molecular pharmaceutics.

[113]  Sabrina Pricl,et al.  Poly(amidoamine)-based dendrimer/siRNA complexation studied by computer simulations: effects of pH and generation on dendrimer structure and siRNA binding. , 2012, Macromolecular bioscience.

[114]  P. Kesharwani,et al.  Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.

[115]  D. Appelhans,et al.  Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer. , 2014, International journal of pharmaceutics.

[116]  Keerti Jain,et al.  Dendrimer as nanocarrier for drug delivery , 2014 .

[117]  D. Owen,et al.  Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. , 2011, Molecular pharmaceutics.

[118]  B. Kelly,et al.  The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. , 2008, Molecular pharmaceutics.

[119]  P. Sontum,et al.  Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers : Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents , 1997 .

[120]  Francis C Szoka,et al.  Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. , 2002, Bioconjugate chemistry.

[121]  Ryan M. Pearson,et al.  Dendron-mediated self-assembly of highly PEGylated block copolymers: a modular nanocarrier platform. , 2011, Chemical communications.

[122]  Ryan M. Pearson,et al.  Poly(ethylene glycol) Corona Chain Length Controls End-Group-Dependent Cell Interactions of Dendron Micelles , 2014, Macromolecules.

[123]  Mary J Cloninger,et al.  Biological applications of dendrimers. , 2002, Current opinion in chemical biology.

[124]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[125]  H. Gu,et al.  Synthesis and gene delivery of poly(amido amine)s with different branched architecture. , 2010, Biomacromolecules.

[126]  A. Elhissi,et al.  PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. , 2014, International journal of pharmaceutics.

[127]  M. Grinstaff,et al.  Therapeutic and diagnostic applications of dendrimers for cancer treatment. , 2008, Advanced drug delivery reviews.

[128]  R. Roy,et al.  Synthesis and lectin binding properties of dendritic mannopyranoside , 1996 .

[129]  Seungpyo Hong,et al.  Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells. , 2014, Nanoscale.

[130]  Thommey P. Thomas,et al.  PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic. , 2014, Biomacromolecules.

[131]  P. Low,et al.  Avidity Mechanism of Dendrimer–Folic Acid Conjugates , 2014, Molecular pharmaceutics.

[132]  Ryan M. Pearson,et al.  Positively Charged Dendron Micelles Display Negligible Cellular Interactions. , 2013, ACS macro letters.

[133]  M. Brechbiel,et al.  Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.

[134]  S. Pricl,et al.  Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer. , 2014, Journal of medicinal chemistry.